Skip to main content
Clinical Trials/NCT00984776
NCT00984776
Completed
Not Applicable

Detection of Vulnerable Plaque With Coronary Vessel Wall MRI: Contrast Enhanced MRI With Gadofosveset MS-325.

Maastricht University Medical Center1 site in 1 country20 target enrollmentMarch 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Maastricht University Medical Center
Enrollment
20
Locations
1
Primary Endpoint
Validation of MRI: comparison with IVUS. Can plaque be detected?
Status
Completed
Last Updated
16 years ago

Overview

Brief Summary

MRI has the ability to visualize the arterial vessel wall. Wall thickening and atherosclerotic plaque components can be visualized in the carotid arteries and the aorta. Previous studies also demonstrated the ability of MRI to visualize the coronary vessel wall. The ultimate goal of coronary vessel wall imaging is to detect vulnerable atherosclerotic plaque thereby. This might prevent complications, e.g., chest pain (angina) or myocardial infarction.

The goal of this study was to validate MRI of the coronary vessel wall by comparing it to intravascular ultrasound (IVUS), to detect atherosclerotic plaque in the coronary vessel wall and to look at the uptake of the albumin-binding contrast agent gadofosveset in atherosclerotic plaques. The main hypothesis is that due to the albumin binding characteristics, uptake of the contrast agent will take place in the more vulnerable plaques compared to less vulnerable plaques. MRI will be compared to X-ray coronary angiography and intravascular ultrasound, two techniques currently considered as the standard of reference for imaging of the coronary arteries and vessel wall.

Registry
clinicaltrials.gov
Start Date
March 2007
End Date
February 2009
Last Updated
16 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • scheduled X-ray angiography for known coronary artery disease, valvular disease or chest pain with unknown origin
  • age \> 18 yrs and \< 90 yrs
  • Informed consent

Exclusion Criteria

  • arrhythmia
  • hemodynamic unstable patients
  • contra-indications for (contrast-enhanced) MRI
  • age \< 18 yrs or \> 90 yrs

Outcomes

Primary Outcomes

Validation of MRI: comparison with IVUS. Can plaque be detected?

Time Frame: 1 week

Secondary Outcomes

  • uptake contrast agent gadofosveset in atherosclerotic plaque in the coronary vessel wall?(1 day)

Study Sites (1)

Loading locations...

Similar Trials